Exam Scores vs Reality: The 2026 AI Index Report on Medicine

We unpack the Stanford AI Index 2026 Medicine chapter to explore why AI is acing medical exams but still struggling to translate into prospective clinical trial evidence. We dive into the massive gap between FDA clearances and randomized trials, highlight which tools like ambient scribes are genuinely scaling, and reveal why smaller models are outperforming massive systems in molecular biology.

Key points

• Leading multi-agent AI systems score 85.5% on complex medical cases compared to 20% for physicians, yet nearly half of clinical AI studies still rely on simulated scenarios rather than real patient data.
• Ambient AI scribes are driving real clinical impact, with some health systems reporting an 83% reduction in note-writing effort and up to a 112% return on investment.
• The FDA authorized 258 AI medical devices in 2025, but a peer-reviewed analysis found that only 2.4% of devices with clinical studies were supported by randomized controlled trial data.
• In molecular biology, smaller specialized models are outperforming massive general-purpose systems, and biological model development is increasingly bottlenecked by data curation rather than architecture.
• AI-generated summaries now appear at the top of 84% to 92% of health-related Google searches, fundamentally shaping how patients access health information before ever seeing a clinician.

Source: Medicine - Stanford Institute for Human-Centered Artificial Intelligence, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/exam-scores-vs-reality-the-2026-ai-index-report-on-medicine-ec9148